OA08901A - Elaboration of host defense mediators into biological fluids by systemic DSRNA treatment. - Google Patents

Elaboration of host defense mediators into biological fluids by systemic DSRNA treatment.

Info

Publication number
OA08901A
OA08901A OA59407A OA59407A OA08901A OA 08901 A OA08901 A OA 08901A OA 59407 A OA59407 A OA 59407A OA 59407 A OA59407 A OA 59407A OA 08901 A OA08901 A OA 08901A
Authority
OA
OAPI
Prior art keywords
biological fluids
elaboration
host defense
various
systemic
Prior art date
Application number
OA59407A
Other languages
English (en)
Inventor
William A Carter
Original Assignee
Hem Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Res Inc filed Critical Hem Res Inc
Publication of OA08901A publication Critical patent/OA08901A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
OA59407A 1987-08-12 1988-08-12 Elaboration of host defense mediators into biological fluids by systemic DSRNA treatment. OA08901A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8422787A 1987-08-12 1987-08-12

Publications (1)

Publication Number Publication Date
OA08901A true OA08901A (en) 1989-10-31

Family

ID=22183617

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59407A OA08901A (en) 1987-08-12 1988-08-12 Elaboration of host defense mediators into biological fluids by systemic DSRNA treatment.

Country Status (19)

Country Link
EP (1) EP0308066B1 (fr)
JP (1) JPH01131119A (fr)
KR (1) KR0131879B1 (fr)
CN (1) CN1050995C (fr)
AT (1) ATE132041T1 (fr)
AU (3) AU2053588A (fr)
CA (1) CA1327002C (fr)
DE (1) DE3854829T2 (fr)
DK (1) DK449888A (fr)
FI (1) FI883763A7 (fr)
HU (1) HUT47854A (fr)
IE (1) IE72103B1 (fr)
IL (1) IL87413A0 (fr)
NO (1) NO883594L (fr)
NZ (1) NZ225799A (fr)
OA (1) OA08901A (fr)
PT (1) PT88266B (fr)
RU (1) RU1834663C (fr)
ZA (1) ZA885967B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593973A (en) * 1987-09-04 1997-01-14 Hemispherx Biopharma Inc. Treatment of viral hepatitis with mismatched dsRNA
EP0306347B1 (fr) * 1987-09-04 1995-05-10 Hem Pharmaceuticals Corp. Diagnostic des déficiences en RNA double-brin
US4963532A (en) * 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
EP0378621A4 (en) * 1988-05-23 1991-08-28 Steffen Gay Diagnostics and therapy for rheumatoid arthritis
EP0473576A4 (en) * 1989-05-19 1993-03-10 Hem Research, Inc. Short therapeutic dsrna of defined structure
ZA908037B (en) * 1989-10-11 1991-09-25 Hem Res Inc Protection from shock subsequent to injury by double-standed rnas
WO1991005560A1 (fr) * 1989-10-11 1991-05-02 Hem Research, Inc. Protection contre un choc posterieur a une blessure a l'aide d'arn bicatenaires
HUT65370A (en) * 1989-10-16 1994-05-02 Hem Res Inc Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
CA2120027A1 (fr) * 1991-09-26 1993-04-01 William A. Carter Methode de neutralisation des effets du il-1 au moyen d'arm bicatenairse
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999049029A1 (fr) 1998-03-20 1999-09-30 Benitec Australia Ltd Controle d'expression genique
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1147204A1 (fr) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition et methode destinees a l'attenuation in vivo et in vitro de l'expression genique utilisant de l'arn double brin
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
CA2369944A1 (fr) 2001-01-31 2002-07-31 Nucleonics Inc. Utilisation de l'inhibition genetique post-transcriptionnelle pour identifier les sequences d'acides nucleiques qui modulent la fonction d'une cellule
CA2482903A1 (fr) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Moyens et procedes pour l'inhibition specifique de genes dans les cellules et le tissu du systeme nerveux central et/ou de l'oeil
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004022075A1 (fr) * 2002-09-04 2004-03-18 Novartis Ag Traitement de troubles neurologiques par administration d'arn bicaténaire
EP2134172A4 (fr) * 2007-03-05 2011-06-01 Univ Utah State Agoniste restrictif du récepteur 3 de type toll (tlr3)
CA2745832A1 (fr) 2008-12-04 2010-06-10 Opko Ophthalmics, Llc Compositions et procedes pour l'inhibition selective d'isoformes pro-angiogeniques de vegf
CN109355334A (zh) * 2018-12-06 2019-02-19 江苏省农业科学院 一种制备聚肌胞的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1326450C (fr) * 1985-08-26 1994-01-25 William A. Carter Modulation des manifestations associees au virus du sida au moyen d'arn a double brin
AU1820388A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles

Also Published As

Publication number Publication date
ATE132041T1 (de) 1996-01-15
CA1327002C (fr) 1994-02-15
FI883763L (fi) 1989-02-13
NO883594L (no) 1989-02-13
PT88266A (pt) 1989-06-30
EP0308066A2 (fr) 1989-03-22
EP0308066B1 (fr) 1995-12-27
DE3854829T2 (de) 1996-08-14
KR890003402A (ko) 1989-04-14
DK449888A (da) 1989-02-13
IL87413A0 (en) 1989-01-31
DE3854829D1 (de) 1996-02-08
DK449888D0 (da) 1988-08-11
EP0308066A3 (fr) 1991-01-16
FI883763A0 (fi) 1988-08-12
RU1834663C (ru) 1993-08-15
NO883594D0 (no) 1988-08-12
AU2053588A (en) 1989-04-20
PT88266B (pt) 1995-05-04
CN1032740A (zh) 1989-05-10
FI883763A7 (fi) 1989-02-13
JPH01131119A (ja) 1989-05-24
AU1001595A (en) 1995-02-23
ZA885967B (en) 1989-07-26
IE72103B1 (en) 1997-03-12
AU1736792A (en) 1992-07-30
CN1050995C (zh) 2000-04-05
HUT47854A (en) 1989-04-28
IE882399L (en) 1989-02-12
NZ225799A (en) 1991-04-26
KR0131879B1 (ko) 1998-04-17

Similar Documents

Publication Publication Date Title
ZA885967B (en) Elaboration of host defense mediators into biological fluids by systemic dsrna treatment
DK345484A (da) Projektil til ildvaaben
AU1256288A (en) Treatment of human viral infections by dsrna combined with viral inhibitors
IE862276L (en) PREVENTION AND TREATMENT OF AIDS WITH dsRNA
EP0500893A4 (en) Preservation of blood, tissues and biological fluids
BR0112919A (pt) Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter
GR3022801T3 (en) Phenylalkan(en)oic acids with leukotriene B4 antagonistic activity.
IE900073L (en) Treatment of diseases associated with hiv infections
ES2099700T3 (es) Anilidas de acido 5-metil-isoxazol-4-carboxilico y anilidas de acido 2-hidroxietilidenciano para el tratamiento de enfermedades oculares.
ES2053039T3 (es) Procedimiento para impedir el cambio de color de los alimentos.
DK178188A (da) Antivirusmiddel
AU6751294A (en) Protection from shock subsequent to injury by double-standard RNAs
KR900017587A (ko) 바이러스 감염증 치료제의 제조를 위한 티아졸 유도체 티프로티모드의 용도
DE69110470D1 (de) Herstellung von erhöhten Biokontrollwirkstoffen.
Wargo Interaction of stress and secondary organisms in decline of forest trees.
JPS5736981A (en) Solution composition of liquefied spirulina and its preparation
PT83247B (pt) Processo para a preparacao de hidroxialquil-fenoxi-propan-2-olaminas uteis como beta-bloqueadores oculosselectivos
Youmans Host-bacteria interactions: External defense mechanisms.
RU92015278A (ru) Средство, стабилизирующее витамины групп с, р, в и а и повышающее биологическую ценность пищевых продуктов
Pavlovskis et al. Experimental Pseudomonas aeruginosa infections in burned mice and rats: Description of a model.
Kosmidis TREATMENT OF SERIOUS INFECTIONS WITH CEFTRIAXONE
Kurnick et al. Effect of stilbamidine on ascites tumor of mice
Oomomo et al. Glucose nonfermentative gram-negative rods isolated from ocular infection.
ES2194860T3 (es) Composiciones que contienen timosina alfa 1 destinadas al tratamiento de pacientes que sufren una enfermedad hepatica descompensada.
RU92002700A (ru) Способ лечения острого подагрического артрита